WAVE Life Sciences Ltd
WVE7.260USD
+0.210+2.98%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
More Details of WAVE Life Sciences Ltd Company
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
WAVE Life Sciences Ltd Info
Ticker SymbolWVE
Company nameWAVE Life Sciences Ltd
IPO dateNov 11, 2015
CEODr. Paul B. Bolno, M.D.
Number of employees287
Security typeOrdinary Share
Fiscal year-endNov 11
Address7 Straits View
City
Stock exchangeNASDAQ Global Market Consolidated
CountrySingapore
Postal code018936
Phone6562363388
Websitehttps://www.wavelifesciences.com/
Ticker SymbolWVE
IPO dateNov 11, 2015
CEODr. Paul B. Bolno, M.D.
Company Executives of WAVE Life Sciences Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
40.39K
+150.62%
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
+78.81%
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+48.58%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
19.14K
+18.80%
Dr. Paul B. Bolno, M.D.
Dr. Paul B. Bolno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher John Francis, Ph.D.
Dr. Christopher John Francis, Ph.D.
Senior Vice President - Corporate Development, Head - Emerging Areas
Senior Vice President - Corporate Development, Head - Emerging Areas
--
--
Dr. Gregory L. (Greg) Verdine, Ph.D.
Dr. Gregory L. (Greg) Verdine, Ph.D.
Director
Director
--
--
Dr. Peter Kolchinsky, Ph.D.
Dr. Peter Kolchinsky, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
40.39K
+150.62%
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
+78.81%
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+48.58%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
19.14K
+18.80%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Nov 4
Updated: Tue, Nov 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
5.50%
Maverick Capital, Ltd.
5.19%
Other
57.91%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
5.50%
Maverick Capital, Ltd.
5.19%
Other
57.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.83%
Hedge Fund
24.54%
Investment Advisor/Hedge Fund
19.04%
Corporation
15.30%
Venture Capital
11.51%
Research Firm
1.88%
Individual Investor
0.49%
Bank and Trust
0.29%
Pension Fund
0.21%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
368
140.86M
88.47%
+5.01M
2025Q2
364
156.69M
98.46%
-1.61M
2025Q1
368
156.82M
101.38%
+1.16M
2024Q4
342
152.89M
100.27%
+6.14M
2024Q3
306
144.44M
97.59%
+25.71M
2024Q2
274
116.00M
94.13%
+429.46K
2024Q1
255
115.83M
95.69%
+2.66M
2023Q4
240
115.18M
98.42%
+19.70M
2023Q3
224
93.79M
97.86%
+5.83M
2023Q2
224
93.41M
97.80%
+7.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
18.21M
11.44%
+12.70K
+0.07%
Aug 11, 2025
GSK plc
16.78M
10.54%
--
--
Jun 06, 2025
Adage Capital Management, L.P.
15.02M
9.43%
+2.50M
+19.97%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.75M
5.5%
+540.89K
+6.59%
Jun 30, 2025
Maverick Capital, Ltd.
8.26M
5.19%
--
--
Jun 30, 2025
Driehaus Capital Management, LLC
6.53M
4.1%
+172.92K
+2.72%
Jun 30, 2025
Shin Nippon Biomedical Laboratories Ltd
5.71M
3.58%
--
--
Jun 06, 2025
M28 Capital Management LP
5.66M
3.56%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
5.08M
3.19%
+1.05M
+26.08%
Jun 30, 2025
Emerald Advisers LLC
5.19M
3.26%
+130.23K
+2.57%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
1.35%
Global X Genomics & Biotechnology ETF
1.04%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.73%
iShares U.S. Pharmaceuticals ETF
0.33%
First Trust Multi-Manager Small Cap Opportunities ETF
0.22%
Franklin Genomic Advancements ETF
0.17%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
View more
SPDR S&P Pharmaceuticals ETF
Proportion1.35%
Global X Genomics & Biotechnology ETF
Proportion1.04%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.01%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.73%
iShares U.S. Pharmaceuticals ETF
Proportion0.33%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.22%
Franklin Genomic Advancements ETF
Proportion0.17%
iShares Micro-Cap ETF
Proportion0.16%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
